Advertisement Arkray wins FDA clearance for new blood glucose monitoring system - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Arkray wins FDA clearance for new blood glucose monitoring system

Arkray USA, a blood glucose monitoring company, has received the 510(k) clearance from the FDA for the Glucocard 01-mini blood glucose monitoring system.

According to the company, this new system requires no coding, displays results in seven seconds, requires a tiny 0.3 micro liter sample size, and was developed to use the same affordable test strips as the downloadable Glucocard 01 system that launched in 2008. Glucocard 01-mini has AST and features pre/post meal flags.

The Glucocard 01-mini is believed to be the only system on the market that features interchangeable faceplates so users may personalize the look of their monitoring system. It also features an easy-to-read display. The Glucocard 01-mini is distinguished by its design and technology. Recent clinical data showed Glucocard 01-mini to be highly accurate, precise and easy-to-use, the company said.

Jonathan Chapman, president of Arkray USA, said: “Arkray is excited to announce a new addition to our growing line of Glucocard blood glucose monitoring systems. The Glucocard 01-mini system follows the Glucocard brand image of sleek, compact, and discreet. The Glucocard 01-mini is unlike other glucose monitors in the market, it features interchangeable face plates.”